Renal function in abdominal neuroblastoma patients undergoing proton radiotherapy.
Pediatr Blood Cancer
; 70(1): e29981, 2023 01.
Article
in En
| MEDLINE
| ID: mdl-36129239
ABSTRACT
BACKGROUND:
The purpose of this study is to analyze renal function outcomes in abdominal neuroblastoma patients undergoing proton therapy (PT). PROCEDURE From 2011 to 2019, two single-institution Institutional Review Board-approved protocols prospectively enrolled neuroblastoma patients for data collection. To assess renal function, serum creatinine (Cr), blood urea nitrogen (BUN), and creatinine clearance (CrCl) before proton therapy (pre-PT) were compared with the values at last follow-up.RESULTS:
A total of 30 children with abdominal neuroblastoma with median age 3.5 years (range, 0.9-9.1) at time of PT were included in this study. All patients underwent chemotherapy and resection of primary tumor prior to PT. Two patients required radical nephrectomy. Median follow-up after PT was 35 months. Mean dose to ipsilateral and contralateral kidney was 13.9 and 5.4 Gy, respectively. No patients developed hypertension or renal dysfunction during follow-up. There was no statistically significant change in serum BUN (p = .508), CrCl (p = .280), or eGFR (p = .246) between pre-PT and last follow-up.CONCLUSION:
At a median follow-up of almost 3 years, renal toxicity was uncommon after PT. Longer follow-up and larger patient cohort data are needed to further assess impact of PT on renal function in this population.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Proton Therapy
/
Neuroblastoma
Type of study:
Etiology_studies
/
Guideline
/
Observational_studies
/
Prognostic_studies
Limits:
Child
/
Child, preschool
/
Humans
Language:
En
Journal:
Pediatr Blood Cancer
Journal subject:
HEMATOLOGIA
/
NEOPLASIAS
/
PEDIATRIA
Year:
2023
Type:
Article
Affiliation country:
United States